- Benchmark ASINB0F8QCT5SB
- MarketplaceUK
- Category ID2805370031
- Analyzed Products
- Keywordtone up sun cream
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2026-07-23
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
结论很直接：这个市场不建议进入，已经是明显的价格战市场，对小品牌尤其不友好。 新品牌里只有 medicube 这一条线跑通，且样本极少；与此同时，最近新进入的 mixsoon 和 rom&nd 都没赚到钱，说明这不是“机会很多”，而是“少数强势品牌吃掉了结果”。
证据上，市场已经在向低利润和极限竞争收缩。 新品可验证的盈利区间只有 14.63%~22.28%，但实际新品牌新发品里只有 33.33% 盈利；按新品牌口径看，2 个新品牌里仅 1 个有盈利新产品，成功率 50.00%，但样本只有 2 个品牌、3 个新发品，不能把它当成宽松市场。更关键的是，样本里出现了 Garnier 这类老品牌用 £9.29 打到 -0.07% 利润的产品，已经是很典型的压价信号；而失败样本 mixsoon B0FK74LR3M（£15.00，37 个评论）和 rom&nd B0H1ZBR4BD 都没跑通，说明常规打法进场很难。成功样本 medicube B0F8QCT5SB 的确盈利，利润率 17.09%，月销 50、月营收 £992.50，投入约 £1299.49 美元，但它依赖品牌势能和差异化提亮防晒卖点，不是低门槛可复制样本；失败样本普遍都指向“同质化、市场小、竞争极端”，并没有看到足够多的真实小品牌成功案例。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
New Brands
Old Brands
#Budget Requirement
Listing不建议进入这个市场。 你的预算 50万 CNY 只能覆盖少数单品的前期铺货、物流和投放，但这个市场已经明显偏向价格竞争，盈利空间不稳，且对新品牌非常不友好。
Early sourcing + logistics + marketing budget (GBP)N/AExplains the budgetWith all these investments, who has profitable new releases
How many new listings are released by old brands?33.33%New listing success rate (old brands):0.00%New listing success rate (new brands):50.00%Which new brands have these successful new listings?Alternatives- 普通防晒乳/防晒霜（非“提亮/校色”型）——通常更便宜、选择更多，适合只想完成基础防晒而不追求即时润色的人群。
- 有色防晒霜/带轻微润色的底妆防晒——如果用户真正需求是“提亮肤色+防晒”，这类产品通常覆盖更完整，替代“tone up sun cream”更直接。
- 妆前乳/隔离霜（带SPF版本）——更容易被当作日常底妆一步到位使用，尤其适合想省步骤、顺便修饰肤色的用户。
- BB霜/CC霜（自带防晒值）——对只想要轻度遮瑕、提亮和防晒的用户来说，往往比单独购买tone up sun cream更实用，也更容易接受。
- 粉底液+单独基础防晒的组合——如果用户更在意妆效稳定性，这个组合替代性强；其中基础防晒可选更平价的大众款，整体可替代成本可控。
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing结论：这个市场不建议进入，尤其不适合小品牌。 现有数据只看到1个新品牌成功、1个新品牌失败，样本太小但方向很明确：新品牌成功率只有50%，而新品牌整体新发品盈利率只有33.33%；同时已出现老品牌用9.29英镑低价打到-0.07%利润的价格战信号，说明竞争已经开始向极限压价走。
New products with Highest revenuemedicube
Recent Monthly Revenue (GBP):£992.50(50pcs/month)B0F8QCT5SB (4.6/5 (66 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableOld brand with the most profitable new productsGarnier
Recent Monthly Revenue (GBP):£92,900.00(10000pcs/month)B0CNQ11ZYH (4.5/5 (6898 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseNet profit margin below 10.00%Most investment in new productsLeast profitable new productsLeast investment in new productsmixsoon
Recent Monthly Revenue (GBP):-(-)B0FK74LR3M (4.5/5 (37 Reviews))Brand is a new entry in this marketNew ReleaseInsufficient Sales to Meet MOQUnderperformingNot enough sales volume to meet 100 MOQ#Differentiations
Unique productsCommon productsDifferentiation:- 气垫粉盒包装，形态和常见管状防晒差异大
- |
- 防晒+润色+保湿三合一，适合通勤补涂
- |
- 偏提亮肤色，适合想要轻底妆效果的人群
B0BX9BQWZ4 (3.8/5 (46 Reviews))Brand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQSales & BSR
Differentiation:- 粉色提亮防晒，外观和定位很鲜明
- |
- 软管极简白粉配色，日常妆前感强
- |
- 主打Tone Up修饰气色，适合轻妆用户
B0F8QCT5SB (4.6/5 (66 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableSales & BSR
#Net Profit Margins: All vs New
Listing这不是适合进入的市场。 结果很清楚：新品里只有1个可验证盈利样本、1个亏损样本，当前更像是靠品牌力和投放硬撑的窄门，而不是适合小卖家稳定切入的机会。
Profitability difficultyModerate Risk Due to Price CompetitionAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%otherNew products distribution on different profit levels
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Profitable Products
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
B00GY2IF78ISDIN2014-05-30Yes£27.4750pcs£1373.525.52%£350.52B0F8QCT5SBmedicube2025-12-03Yes£19.8550pcs£992.517.09%£169.62Top 20 Profitable New Products
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
B0F8QCT5SBmedicube2025-12-03Yes£19.8550pcs£992.517.09%£169.62#New Product Success Rates
Listing这个市场不适合现在进入，结论很明确：已经接近/进入价格战区，且新品牌成功面极窄。 现有数据里，整体可判定的样本中只有25.00%产品盈利，新上架产品盈利率只有33.33%，而真正由新品牌拿到的成功几乎只剩 medicube 的 B0F8QCT5SB，其他新品牌样本 mixsoon、rom&nd 都是失败；这说明不是“机会很多”，而是成功集中在少数强势品牌，竞争壁垒高。
证据很直接：medicube 的 B0F8QCT5SB 以 17.1% 利润率、最近月销 50 单、月营收 992.50 GBP、早期投入 1299.49 USD 跑出正向结果，但它并不是低门槛机会——它依赖 白帽新品打法 和品牌力，且只有 66 个评论，属于少数可复制性很弱的赢家；反过来，旧品牌 ISDIN 的 B00GY2IF78 虽然盈利、评论高达 10246，但它属于成熟大牌常规盘，B0H1ZBR4BD（rom&nd）和 B0FK74LR3M（mixsoon）都没跑通，说明新品牌想靠常规打法进入很难。从市场结构看，盈利产品被少数品牌占住，失败产品也集中在新释放里，典型是“强品牌吃肉、后来者挨打”的格局，不是开放型增量市场。
对大品牌：可以打，但要按高预算、强品牌、强投放来做，不是轻量试错市场；对小品牌：不建议进入。 你当前预算 500000 CNY 在表面上够，但这类市场真正卡点不只是首批货+广告，而是长期品牌建设、研发和持续投放；若没有明显差异化和额外预算，想复制 medicube 这种结果风险很高。小品牌若要硬进，只能找低评论、真实销量、利润率≥15% 的真成功样本，但现有数据里几乎看不到可作为小品牌正面标杆的案例，所以结论是：不要进，至少不要按普通新品逻辑进。
New products success rate.
What is the ratio of profitable products
Profitable (Unidentifiable released date)Profitable (Old product)Profitable (New product)Profitable (New product on old listing)New products but non profitableProfitable new products divide by brands
What is the ratio of different brands owning all profitable new products
medicubeNonprofitable new products divide by brands
What is the ratio of different brands owning all nonprofitable new products
rom&ndmixsoon#Success Rate by Entry Time
Listing这个市场不值得进入，已经进入高风险/接近饱和区。 现有数据里，新进入品牌只有1个成功、1个失败，最近新品牌成功率只有50%，但样本极小，不能掩盖市场已经出现的明显价格与竞争压力；更关键的是，最近出现的可验证新品牌里，只有 medicube 这条线真正跑通，另一个新品牌 mixsoon 直接亏损，说明新人并不是普遍容易成功。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 1 0 0 0 1 2026 0 0 0 0 0 0 0 1 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 0 0 0 0 2025/9 0 0 0 0 0 0 0 1 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 0 0 0 0 2025/12 0 0 0 1 0 0 0 0 2026/1 0 0 0 0 0 0 0 0 2026/2 0 0 0 0 0 0 0 0 2026/3 0 0 0 0 0 0 0 0 2026/4 0 0 0 0 0 0 0 0 2026/5 0 0 0 0 0 0 0 1 2026/6 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success CasesISDIN Fotoultra 100 Active Unify Color Spf 50+ 50ml | Facial Sun Cream | Lightens and unifies skin tone
This listing is deemed profitablePrice (GBP)£27.47Released TypeOld Release (2014-05-30)Brand is an old entry in this marketSize and Weight11.0 x 5.0 x 2.5 cm, 74.00gProfitable Factors
Established brand with longevityBased on old ASINDesign & Appearance
带色号的润色型防晒，主打提亮和均匀肤色, 轻薄流体质地的面部防晒，属于成熟常见公模配方形态Key Buying Motive
含三重淡斑/均匀肤色卖点，兼顾高倍防晒与遮瑕润色Target Customers
有色斑、肤色不均、需要日常防晒同时修饰肤色的人群Early Investment
Investment
Monthly Revenue (Recent) (GBP)£1,373.5050 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight25.50% / 25.52%Peak / Non PeakRail Freight24.41% / 24.43%Peak / Non PeakAir Freight24.41% / 24.43%Peak / Non PeakSales & BSR Performance
medicubeB0F8QCT5SB (4.6/5 (66 Reviews))medicube Pink Tone Up Sun Cream
This listing is deemed profitablePrice (GBP)£19.85Released TypeNew Release (2025-12-03)Brand is a new entry in this marketSize and Weight14.9 x 4.3 x 3.6 cm, 50.00gProfitable Factors
Established brand with longevityDistinct functions and featuresDesign & Appearance
粉色调的提亮型防晒，更偏向肤色修饰而非单纯防晒, 管状软管包装，整体极简白粉配色，呈现温和的韩系提亮防晒定位Key Buying Motive
主打Tone Up提亮与防晒合一，适合日常快速改善气色Target Customers
想要带自然提亮效果、同时追求日常通勤防晒的轻妆用户Early Investment
Investment
Monthly Revenue (Recent) (GBP)£992.5050 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight17.04% / 17.09%Peak / Non PeakRail Freight16.02% / 16.07%Peak / Non PeakAir Freight16.02% / 16.07%Peak / Non PeakSales & BSR Performance